Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future PipelineSHENZHEN, China, Sept. 8 /PRNewswire-Asia/ -- Shenzhen Beike Biotechnology Co. Ltd. (www.beikebiotech.com), a leader in stem cell research and regenerative medicine, announced the appointment of two senior stem cell scientists to key positions in the company. Li Tao, Ph.D., joins as Lab Director of the iPS (induced Pluripotent Stem Cell) Laboratory, and Susan Jiang, M.D., Ph.D., has been named Chief Science Officer. Dr. Sean Hu, Ph.D., CEO and Chairman, will remain focused on furthering the company's research achievements while strengthening its position in the international biotechnology field. Dr. Hu commented, "Beike has been at the forefront of stem cell technology in China and we are currently expanding throughout Asia. We are addressing a number of important factors to strengthen our credentials internationally, and we see Dr. Li Tao and Dr. Susan Jiang contributing greatly to this effort. Dr. Jiang will spearhead our initiatives to enhance our current technologies and increase their acceptance by the Western scientific community while Dr. Tao will lead a group developing a pipeline of emerging technologies for the coming five to ten years." |
|
|
|
|
|
|
| Page 3 of 3 |